HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.

AbstractBACKGROUND AND OBJECTIVES:
The aim of this prospective, randomized, 1-year study was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations of parenteral desferrioxamine (DFO) with oral DFP.
DESIGN AND METHODS:
A total of 24 patients with thalassemia major were randomized to receive one of the following two treatments; DFP given at a daily dose of 75 mg/kg in combination with DFO (40-50 mg/kg twice weekly) (n=12) or as single agent (n=12). In addition, 12 patients treated with 40-50 mg/kg DFO 5 days weekly were included as a reference group without randomization. Changes in liver iron concentration (LIC) and serum ferritin (SF) were assessed; total iron excretion (TIE), urinary iron excretion (UIE) and iron balance were calculated. Cardiac function and toxicity were also examined.
DESIGN AND METHODS:
SF and LIC were significantly reduced after 1 year of combination therapy (p=0.01 and 0.07, respectively). A decrease of LIC was observed in all but one patient (87.5%) following the combination therapy but in only 42% of patients treated with DFP monotherapy. In the DFO reference group, a statistically significant decrease in LIC (p=0.01) associated with a substantial decrease in SF (p=0.08) was observed after 1 year. The combination regimen resulted in greater TIE compared to DFP monotherapy (p=0.08) and was the regimen associated with the highest iron balance compared to DFP monotherapy (p=0.04) or standard DFO treatment (p=0.006).
INTERPRETATIONS AND CONCLUSIONS:
The addition of subcutaneous DFO twice weekly to oral DFP 75 mg/kg is a highly efficacious and safe chelation therapy providing superior chelation activity to that of DFP and likely has an efficacy profile comparable to that of standard DFO.
AuthorsYesim Aydinok, Zulal Ulger, Deniz Nart, Aysen Terzi, Nurten Cetiner, Gareth Ellis, Arthur Zimmermann, Chantal Manz
JournalHaematologica (Haematologica) Vol. 92 Issue 12 Pg. 1599-606 (Dec 2007) ISSN: 1592-8721 [Electronic] Italy
PMID18055982 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Pyridones
  • Siderophores
  • deferiprone
  • Ferritins
  • Iron
  • Deferoxamine
Topics
  • Adolescent
  • Adult
  • Child
  • Deferoxamine (administration & dosage)
  • Female
  • Ferritins (blood)
  • Humans
  • Iron (blood, urine)
  • Liver (metabolism)
  • Male
  • Pyridones (administration & dosage)
  • Siderophores (administration & dosage)
  • Time Factors
  • beta-Thalassemia (blood, drug therapy, urine)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: